Journal profile · Medicine-Immunology and Allergy
Journal of Asthma and Allergy
ISSN 1178-6965 · Dove Medical Press · NEW ZEALAND
Journal of Asthma and Allergy: CAS Zone 3 · Medicine (2025 upgraded edition); impact factor 3.28; JCR Q2 (journal website); fully open access; APC about USD 4,320; median 84 days to acceptance (105 articles, last 24 months); acceptance rate 20% (journal website); 148 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Journal of Asthma and Allergy is published by Dove Medical Press and is in Zone 3 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Asthma and respiratory diseases, Allergic Rhinitis and Sensitization and Respiratory and Cough-Related Research, together about 49.1% of its articles. Its main subfields are Pulmonary and Respiratory Medicine. (generated from OpenAlex topic counts and CAS ranking data)
Editor-in-Chief: Amrita Dosanjh, MD The Journal of Asthma and Allergy is an international, peer-reviewed journal encompassing all clinical aspects of asthma and allergic diseases, including diagnosis, epidemiology, prevention, management, and treatment. All meta-analyses require a pre-submission check prior to submitting to the Journal of Asthma and Allergy. Please complete the pre-submission check form here. Specific topics covered by the journal include: Allergy Asthma Pulmonary Physiology Primary immune defects Respiratory infections, including transplant related infections Environmental science and asthma/allergy Counselling and patient education in asthma/allergy Cell line and animal only studies will not be considered, studies must include clinical data. Authors are required to provide imaging and diagnostic studies regarding the clinical findings. The Journal of Asthma and Allergy accepts original research, reports, editorials, commentaries, and case series. Case reports and study protocols are considered if they make a valuable and original contribution to the literature. The Journal of Asthma and Allergy will not consider bibliometric analysis studies or bibliometric reviews for publication. When considering submission of a paper utilizing publicly available data authors should ensure that such studies add significantly to the body of knowledge and that they are validated using the authors’ own data through replication in an original sample. Updated 21 May 2026
From the journal's Aims & Scope
Research area (LetPub): Medicine-Immunology and Allergy
Editor-in-chief Amrita DosanjhPublisher website
Editorial board by country: none in mainland China; most named United States 4, United Kingdom 3, Netherlands 2, Denmark 2, Malaysia 2 (22 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Asthma and respiratory diseasesMedicine30.9%
- Allergic Rhinitis and SensitizationMedicine11.3%
- Respiratory and Cough-Related ResearchMedicine6.9%
- Delphi Technique in ResearchSocial Sciences6.2%
- Food Allergy and Anaphylaxis ResearchMedicine5.6%
- Dermatology and Skin DiseasesMedicine4.5%
- Chronic Obstructive Pulmonary Disease (COPD) ResearchMedicine4.5%
- Inhalation and Respiratory Drug DeliveryMedicine4.3%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Allergy | Zone 3 |
| Minor | Immunology | Zone 3 |
| Minor | Respiratory System | Zone 3 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Allergy | Zone 3 |
| Minor | Immunology | Zone 3 |
| Minor | Respiratory System | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Allergy | Zone 3 |
| Minor | Immunology | Zone 3 |
| Minor | Respiratory System | Zone 3 |
Top journal: noReview journal: no
JCR / CiteScore quartiles on the journal's website
- JCR Q2 · best quartile · 2025
- CiteScore Q1 · 2025
Publisher-reported: JCR figures are Clarivate's and CiteScore figures Scopus's to confirm; both are a different system from the CAS zones.Publisher website
Database indexing
SCIEScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
COPEPublisher website
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 3.28LetPub ·
- Impact factor (publisher) 2025
- 3.7Publisher website ·
- 5-year impact factor (publisher)
- 5.8Publisher website ·
- CiteScore 2026-06
- 5.8LetPub ·
- CiteScore (publisher) 2025
- 1.15Publisher website ·
- SJR 2026-06
- 0.98LetPub ·
- SNIP 2026-06
- 1.15LetPub ·
- h-index
- 60OpenAlex ·
- i10-index
- 483OpenAlex ·
- 2-year mean citedness
- 2.94OpenAlex ·
- Self-citation rate
- 3%LetPub ·
- Share of gold OA articles
- 99.19%LetPub ·
Volume
- Articles per year
- 144LetPub ·
- Downloads per year (publisher)
- 162,399Publisher website ·
Articles by year OpenAlex count · 1,127 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 127 | 127 | 29 |
| 2025 | 148 | 148 | 436 |
| 2024 | 117 | 117 | 686 |
| 2023 | 125 | 125 | 1,286 |
| 2022 | 151 | 151 | 2,589 |
| 2021 | 150 | 150 | 3,248 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
84 daysMedian, submission to acceptance · P25–P75 68 days – 111 days
- Acceptance to online
- median 16 days (105 articles)
- Submission to online
- median 104 days
- Sample
- 105 articles with submission and acceptance dates (310 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 16 weeksLetPub ·
- Acceptance rate (publisher)
- 20%Publisher website ·
- Desk decision
- 35 daysPublisher website ·
- Submission to publication (journal-reported)
- about 16 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | USD 4,320 | Yes | CC BY, CC BY-NC | |
| OpenAlex | USD 2,836 | — | — | |
| LetPub | USD 3,300 | Yes | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Article types accepted3
- case reportAuthors may use these detailed descriptions of different paper types accepted by Dove Medical Press (case reports, reviews, etc) to decide how to label their pa…Length not stated
- original researchOriginal ResearchLength not stated
- reviewAuthors may use these detailed descriptions of different paper types accepted by Dove Medical Press (case reports, reviews, etc) to decide how to label their pa…Length not stated
Policy excerpts from the journal's websitePublication ethics, Peer review, Plagiarism
- Publication ethics
COPE member Model summary
This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE).
Source ↗Publisher website ·- Peer review
Accelerated Publication Model summary
This journal offers Accelerated Publication.
Source ↗Publisher website ·- Plagiarism
All submitted manuscripts are checked for plagiarism using Crossref Similarity Check (powered by iThenticate). Model summary
Please be aware that Dove Medical Press checks ALL submitted manuscripts for plagiarism. We use Crossref Similarity Check (powered by iThenticate).
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Dove Medical Press
- Country or region
- NEW ZEALAND
- Language
- English
- ISSN
- 1178-6965
- Official links
- Journal homepage ↗DOAJ
- Author guidelines ↗LetPub
- Aims & Scope ↗LetPub
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗LetPub
- Editorial board ↗LetPub
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Journal of Asthma and Allergy
What CAS zone is Journal of Asthma and Allergy in?
In the 2025 upgraded edition of the CAS Journal Ranking, Journal of Asthma and Allergy is in Zone 3 of Medicine, and in Zone 3 of the minor category Allergy / Immunology / Respiratory System. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Journal of Asthma and Allergy?
The latest impact factor listed by LetPub is 3.28; CiteScore 5.8, h-index 60.
How long does peer review take at Journal of Asthma and Allergy?
Based on the dates recorded on 105 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 84 days (interquartile range 68–111 days); authors report an average review time of about 16 weeks; the journal's website gives an acceptance rate of 20%. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What JCR quartile is Journal of Asthma and Allergy in?
The journal's website gives JCR Q2 (best quartile). JCR quartiles are Clarivate's to confirm and a different system from the CAS zones; in the CAS ranking the journal is in Zone 3 of Medicine.
Where are the editorial board members of Journal of Asthma and Allergy based?
Of the 22 board members whose country the journal's board page names, none are in mainland China; the countries named most often are United States (4), United Kingdom (3) and Netherlands (2). Counted from the institutions listed on the board page; for reference only.
Which databases index Journal of Asthma and Allergy?
According to LetPub and DOAJ records, Journal of Asthma and Allergy is indexed in SCIE, Scopus and DOAJ.
Is Journal of Asthma and Allergy open access, and what is the APC?
Journal of Asthma and Allergy is a fully open-access journal. APC about USD 4,320.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .